Vaxcyte (PCVX) Enterprise Value (2019 - 2026)

Vaxcyte (PCVX) has 8 years of Enterprise Value data on file, last reported at -$1.7 billion in Q1 2026.

• Enterprise Value for Q1 2026 came in at -$1.7 billion, down 3.91% year-over-year; the trailing twelve-month figure through Mar 2026 was -$1.7 billion (down 3.91% YoY), and the FY2025 annual result was -$1.6 billion, up 10.66% from the prior year.
• Enterprise Value fell to -$1.7 billion in Q1 2026 per PCVX's latest filing, from -$1.6 billion in the prior quarter.
• Over five years, Enterprise Value peaked at -$334.6 million in Q1 2022 and troughed at -$2.2 billion in Q3 2024.
• A 5-year average of -$1.3 billion and a median of -$1.5 billion in 2024 frame the typical range for Enterprise Value.
• The sharpest annual moves came in 2022 and 2025: Enterprise Value plunged 278.65% in 2022, then rose 21.52% in 2025.
• A 5-year view of Enterprise Value shows it stood at -$931.4 million in 2022, then declined by 15.98% to -$1.1 billion in 2023, then plunged by 61.74% to -$1.7 billion in 2024, then gained by 10.66% to -$1.6 billion in 2025, then slipped by 11.29% to -$1.7 billion in 2026.
• Business Quant data shows PCVX's Enterprise Value at -$1.7 billion in Q1 2026, -$1.6 billion in Q4 2025, and -$1.7 billion in Q3 2025.